Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

The Impact of Maintenance Lenalidomide on the Mutational Status of the Myeloma Clone at Relapse in the NCRI Myeloma XI Trial for Newly Diagnosed Multiple Myeloma Patients (NDMM)

Blood (2016) 128 (22): 4412.

https://doi.org/10.1182/blood.V128.22.4412.4412

Published: 2016

Journal Articles

Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages; Results of the Phase III Myeloma XI Study

Blood (2016) 128 (22): 1143.

https://doi.org/10.1182/blood.V128.22.1143.1143

Published: 2016

Journal Articles

Primary IMiD Refractory Myeloma; Results from 3894 Patients Treated in the Phase III Myeloma XI Study

Blood (2016) 128 (22): 1144.

https://doi.org/10.1182/blood.V128.22.1144.1144

Published: 2016

Journal Articles

Identifying Ultra-High Risk Myeloma By Integrated Molecular Genetic and Gene Expression Profiling

Blood (2016) 128 (22): 4407.

https://doi.org/10.1182/blood.V128.22.4407.4407

Published: 2016

Journal Articles

A Phase I Dose-Escalation Study of the Class 1 Selective Histone Deacetylase Inhibitor CHR-3996 in Combination with Tosedostat for Patients with Relapsed, Refractory Multiple Myeloma: Results of the Muk Three Trial

Rakesh Popat, Sarah R Brown, Avie-Lee Tillotson, Fiona Collinson, Louise M Flanagan, Cathy D Williams, Kwee L Yong, Gordon Cook, MD PhD, Matthew W Jenner, MD, Martin Kaiser, Jim Cavet, FRCPath, Dima El-Sharkawi, MD, Chin-Hin Ng, MD MRCP, FRCPATH, Eric Low, Gareth J Morgan, MD PhD, Faith E Davies, MD

Blood (2016) 128 (22): 3321.

https://doi.org/10.1182/blood.V128.22.3321.3321

Published: 2016

Journal Articles

Response Adapted Induction Treatment Improves Outcomes for Myeloma Patients; Results of the Phase III Myeloma XI Study

Blood (2016) 128 (22): 244.

https://doi.org/10.1182/blood.V128.22.244.244

Published: 2016

Journal Articles

Impact of Minimal Residual Disease in Transplant Ineligible Myeloma Patients: Results from the UK NCRI Myeloma XI Trial

Ruth Mary de Tute, PhD FRCPath, Andy C Rawstron, BSc, PhD, David A Cairns, MSc, PhD, Charlotte Pawlyn, MB BChir, Faith E Davies, MD, Corinne Collett, Martin F Kaiser, John R Jones, MD, Anna Waterhouse, Alina Striha, MSc, Gordon Cook, MDPhD, Matthew W Jenner, MD, Nigel H Russell, MD, Mark T Drayson, MD PhD, Walter M Gregory, PhD, Graham H Jackson, MD PhD, Gareth J Morgan, MD PhD, Roger G Owen, MD

Blood (2016) 128 (22): 245.

https://doi.org/10.1182/blood.V128.22.245.245

Published: 2016

Journal Articles

DNA Methylation Profiling of Myeloma Trial Patients Reveals Specific Epigenetic Changes Associated with Outcome

Blood (2016) 128 (22): 804.

https://doi.org/10.1182/blood.V128.22.804.804

Published: 2016

Journal Articles

Real-World Use of Pomalidomide and Dexamethasone in Double Refractory Multiple Myeloma: A Multicentre UK Experience

Nicola Maciocia, MBChB, BSc, MRCP, Andrew Melville, MBBS, MA (Cantab), MRCP, Paul Michael Maciocia, BSc, MBBS, MRCP, Simon Cheesman, BPharm, Faye Sharpley, MBBChir, MA, MRCP, MSc, Karthik Ramasamy, MD PhD, Matthew Streetly, BMBS, MRCP, MRCPath, Matthew W Jenner, MD, Reuben Benjamin, MB, BS, FRCPath, Stephen A Schey, MD, Rakesh Popat, Shirley D'Sa, Ali Rismani, MBBS, Kwee L Yong, Neil Rabin

Blood (2016) 128 (22): 3312.

https://doi.org/10.1182/blood.V128.22.3312.3312

Published: 2016

Journal Articles

Quadruplet Vs Sequential Triplet Induction Therapy Approaches to Maximise Response for Newly Diagnosed, Transplant Eligible, Myeloma Patients

Blood (2015) 126 (23): 189.

https://doi.org/10.1182/blood.V126.23.189.189

Published: 2015

Journal Articles

Velcade, Vorinostat and Dexamethasone (V 2 D) in Relapsed Myeloma: Results of the Phase 2 Muk Four Trial

Matthew W Jenner, MD, Avie-Lee Tillotson, Sarah R Brown, Louise M Flanagan, Debbie Sherratt, Charlotte Pawlyn, MB BChir, Cathy Williams, Faith E Davies, MD

Blood (2015) 126 (23): 1852.

https://doi.org/10.1182/blood.V126.23.1852.1852

Published: 2015

Journal Articles

High Resolution Genomic Profiling Using Single Nucleotide Polymorphism Microarrays Identifies Multiple Novel Genomic Minimally Deleted Regions in Multiple Myeloma

Brian A WalKer, PhD, Paola E Leone, PhD, Nicholas J Dickens, DPhil, Matthew W Jenner, MD, Laura Chiecchio, GianPaolo Dagrada, Fiona M Ross, DPhil, Faith E Davies, MD, Gareth J Morgan, MD, PhD

Blood (2008) 112 (11): 625.

https://doi.org/10.1182/blood.V112.11.625.625

Published: 2008

Journal Articles

An Integrated Pharmacogenomic Strategy for the Definition of Thalidomide Response Signatures in Presenting Cases of Multiple Myeloma.

Gareth J. Morgan, MD, PhD, Matthew W. Jenner, MD, Brian A. Walker, PhD, David C. Johnson, BSc, Paola A. Leone, PhD, Fiona M. Ross, PhD, Mark T. Drayson, MD, PhD, Brian G. Van Ness, Brian G. Durie, Nicholas J. Dickens, PhD, J. Anthony Child, R.G. Owen, Faith E. Davies, MD

Blood (2007) 110 (11): 2493.

https://doi.org/10.1182/blood.V110.11.2493.2493

Published: 2007

Journal Articles

Genome-Wide Identification of Gene Expression Networks Affected by Genomic Changes in Multiple Myeloma.

Nicholas J. Dickens, DPhil, Paola E. Leone, PhD, Brian A. Walker, PhD, Matthew W. Jenner, MD, Faith E. Davies, MD, Gareth J. Morgan, MD, PhD

Blood (2007) 110 (11): 2494.

https://doi.org/10.1182/blood.V110.11.2494.2494

Published: 2007

Journal Articles

Integration of Gene Mapping and Expression Arrays Identifies Mechanisms by Which Genes Are Dysregulated as a Result of Copy Number Loss and Gain Associated with IgH Translocations in Multiple Myeloma.

Matthew W. Jenner, MD, Gonzalez David, PhD, Paola E. Leone, PhD, Brian A. Walker, PhD, David C. Johnson, BSc, Nicholas J. Dickens, PhD, Fiona M. Ross, PhD, Faith E. Davies, MD, Gareth J. Morgan, MD, PhD

Blood (2007) 110 (11): 395.

https://doi.org/10.1182/blood.V110.11.395.395

Published: 2007

Journal Articles

Mutation and Methylation Analysis of WWOX and CYLD on 16q; Potential Tumor Suppressor Genes in Myeloma.

Brian A. Walker, PhD, Matthew W. Jenner, MD, Poala E. Leone, PhD, Nicholas J. Dickens, DPhil, David C. Johnson, BSc, Fiona M. Ross, DPhil, Faith E. Davies, MD, Gareth J. Morgan, MD, PhD

Blood (2007) 110 (11): 2473.

https://doi.org/10.1182/blood.V110.11.2473.2473

Published: 2007

Journal Articles

Screening of Homozygous Deletions Identifies Key Deregulated Genes and Pathways in Multiple Myeloma.

Paola E. Leone, PhD, Brian A. Walker, PhD, Nicholas J. Dickens, DPhil, Matthew W. Jenner, MD, David C. Johnson, BSc, Fiona M. Ross, DPhil, Faith E. Davies, MD, Gareth J. Morgan, MD, PhD

Blood (2007) 110 (11): 2474.

https://doi.org/10.1182/blood.V110.11.2474.2474

Published: 2007

Journal Articles

Thalidomide Combinations Improve Response Rates; Results from the MRC IX Study.

Gareth J. Morgan, MD, PhD, Faith E. Davies, MD, Roger G. Owen, MD, Andrew C. Rawstron, PhD, Sue Bell, DPhil, Kim Cocks, MSc, Walter Gregory, Graham Jackson, MD, Mark T. Drayson, PhD, Matthew W. Jenner, MD, James A. Child, MD

Blood (2007) 110 (11): 3593.

https://doi.org/10.1182/blood.V110.11.3593.3593

Published: 2007

Journal Articles

The Combination of Velcade, Idarubicin and Melphalan (VIM) Demonstrates Significant Clinical Activity in Relapsed/Refractory Myeloma Patients.

Faith E. Davies, MD, Muralikrishnan Srikanth, MD, Ping Wu, Matthew W. Jenner, MD, Rita McCormack, Franz Cordero, Géralyn C. Trudel, PhD, Gareth Morgan, PhD

Blood (2007) 110 (11): 2727.

https://doi.org/10.1182/blood.V110.11.2727.2727

Published: 2007

Journal Articles

Thalidomide in Combination with Idarubicin, Dexamethasone and Etoposide (TIDE) Is an Effective Oral Combination in Heavily Pre-Treated Myeloma Patients.

Mark D. Linch, MD, Matthew W. Jenner, MD, Sharon Dines, Faith E. Davies, MD, Gareth J. Morgan, PhD

Blood (2007) 110 (11): 4841.

https://doi.org/10.1182/blood.V110.11.4841.4841

Published: 2007

NARROW

The Impact of Maintenance Lenalidomide on the Mutational Status of the Myeloma Clone at Relapse in the NCRI Myeloma XI Trial for Newly Diagnosed Multiple Myeloma Patients (NDMM)

Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages; Results of the Phase III Myeloma XI Study

Primary IMiD Refractory Myeloma; Results from 3894 Patients Treated in the Phase III Myeloma XI Study

Identifying Ultra-High Risk Myeloma By Integrated Molecular Genetic and Gene Expression Profiling

A Phase I Dose-Escalation Study of the Class 1 Selective Histone Deacetylase Inhibitor CHR-3996 in Combination with Tosedostat for Patients with Relapsed, Refractory Multiple Myeloma: Results of the Muk Three Trial

Response Adapted Induction Treatment Improves Outcomes for Myeloma Patients; Results of the Phase III Myeloma XI Study

Impact of Minimal Residual Disease in Transplant Ineligible Myeloma Patients: Results from the UK NCRI Myeloma XI Trial

DNA Methylation Profiling of Myeloma Trial Patients Reveals Specific Epigenetic Changes Associated with Outcome

Real-World Use of Pomalidomide and Dexamethasone in Double Refractory Multiple Myeloma: A Multicentre UK Experience

Quadruplet Vs Sequential Triplet Induction Therapy Approaches to Maximise Response for Newly Diagnosed, Transplant Eligible, Myeloma Patients

Velcade, Vorinostat and Dexamethasone (V 2 D) in Relapsed Myeloma: Results of the Phase 2 Muk Four Trial

High Resolution Genomic Profiling Using Single Nucleotide Polymorphism Microarrays Identifies Multiple Novel Genomic Minimally Deleted Regions in Multiple Myeloma

An Integrated Pharmacogenomic Strategy for the Definition of Thalidomide Response Signatures in Presenting Cases of Multiple Myeloma.

Genome-Wide Identification of Gene Expression Networks Affected by Genomic Changes in Multiple Myeloma.

Integration of Gene Mapping and Expression Arrays Identifies Mechanisms by Which Genes Are Dysregulated as a Result of Copy Number Loss and Gain Associated with IgH Translocations in Multiple Myeloma.

Mutation and Methylation Analysis of WWOX and CYLD on 16q; Potential Tumor Suppressor Genes in Myeloma.

Screening of Homozygous Deletions Identifies Key Deregulated Genes and Pathways in Multiple Myeloma.

Thalidomide Combinations Improve Response Rates; Results from the MRC IX Study.

The Combination of Velcade, Idarubicin and Melphalan (VIM) Demonstrates Significant Clinical Activity in Relapsed/Refractory Myeloma Patients.

Thalidomide in Combination with Idarubicin, Dexamethasone and Etoposide (TIDE) Is an Effective Oral Combination in Heavily Pre-Treated Myeloma Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only